Antifungal treatment for fungal lung infection with liver problems
Part of Digestive system clinical trials.
This trial tests a stronger antifungal medicine (liposomal amphotericin B) for people with a serious fungal lung infection who also have liver problems. It aims to see if this treatment is safe and effective for ICU patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and currently in the intensive care unit (ICU).
- You need a confirmed or likely diagnosis of invasive aspergillosis, a serious fungal infection usually affecting the lungs.
- You should have mild to moderate liver problems (liver enzymes slightly high, or Child-Pugh class A or B).
- You are expected to need antifungal therapy for at least 5 days.
- You are not pregnant or breastfeeding, have no severe kidney failure (e.g., on dialysis), and have no allergy to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This study compares different antifungal medicines to see which works best for a serious lung fungal infection called pulmonary mucormycosis. If you have this infection and haven't had too much prior treatment, you might be able to join.
This study aims to detect invasive lung aspergillosis earlier by testing samples from your lungs and measuring specific lab markers. It may help doctors start the right antifungal treatment sooner when the infection is suspected.
This study looks at different types of fungi that may cause serious lung infections in patients with weakened immune systems in the ICU. It aims to find out which fungi are present and which antifungal drugs can kill them.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This study will use special scans to see how an inhaled antifungal medicine (amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis. The results may help doctors choose better treatments in the future.
Hear when a new Aspergillosis Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.